title: Complement activation after ischemia-reperfusion in human liver allografts: incidence and pathophysiological relevance.
abstract: OBJECTIVE
  Little is known about the occurrence and possible consequences of local complement activation in human liver transplantation. The aim of this study was to search for signs of complement activation in human liver allografts and evaluate their relationship to cell injury and leukocyte sequestration.
  
  
  METHODS
  In 33 postreperfusion biopsy specimens, 9 preoperative specimens, and 10 intraoperative specimens, the cytolytic membrane attack complex of complement was localized, expression of complement inhibitors was evaluated, and intragraft accumulation of leukocytes and platelets was quantitated.
  
  
  RESULTS
  In control samples and preoperative biopsy specimens, the membrane attack complex was detected only in extracellular deposits, associated with its soluble inhibitors clusterin and vitronectin. Comparable observations were performed in 14 postoperative specimens. In the remaining 19 postoperative specimens, membrane attack complex decorated a variable proportion of hepatocytes. The extent of membrane attack complex deposition correlated with the increase in postoperative aspartate aminotransferase levels in serum (P = 0.002) and the decrease in postoperative factor V levels in serum (P = 0.002). It also correlated with the number of leukocytes and platelets accumulating within the graft (P < or = 0.001).
  
  
  CONCLUSIONS
  Local complement activation is frequent during human liver transplantation and probably contributes to cell injury and leukocyte sequestration in the allograft.
authors.affiliation: Laboratoire de Biologie Cellulaire and INSERM Unite 327, Faculte de Medecine Xavier Bichat, Paris, France.
authors.forename: J Y
authors.initials: JY
authors.lastname: Scoazec
authors.forename: G
authors.initials: G
authors.lastname: Borghi-Scoazec
authors.forename: F
authors.initials: F
authors.lastname: Durand
authors.forename: J
authors.initials: J
authors.lastname: Bernuau
authors.forename: B N
authors.initials: BN
authors.lastname: Pham
authors.forename: J
authors.initials: J
authors.lastname: Belghiti
authors.forename: G
authors.initials: G
authors.lastname: Feldmann
authors.forename: C
authors.initials: C
authors.lastname: Degott
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis; D001706:Biopsy; D015815:Cell Adhesion Molecules; D051152:Clusterin; D003167:Complement Activation; D015938:Complement Membrane Attack Complex / Q000032:analysis; D005260:Female; D006023:Glycoproteins / Q000032:analysis; D006801:Humans; D007511:Ischemia / Q000276:immunology*; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D018832:Molecular Chaperones; D015424:Reperfusion; D014184:Transplantation, Homologous; D019096:Vitronectin / Q000032:analysis
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; C069847:CD66 antigens; C495242:CLU protein, human; D015815:Cell Adhesion Molecules; D051152:Clusterin; D015938:Complement Membrane Attack Complex; D006023:Glycoproteins; D018832:Molecular Chaperones; D019096:Vitronectin